arrow_back Back to App

Prohibiting Pay-for-Delay Drug Deals: Lowering Medication Costs

This act aims to lower drug prices by prohibiting brand-name drug companies from paying generic companies to delay the market entry of cheaper alternatives. This means citizens can expect faster access to more affordable medications, positively impacting their personal finances and healthcare access.
Key points
Bans payments for delaying the market entry of generic and biosimilar drugs, aiming to boost competition.
Introduces financial penalties for companies violating these rules, discouraging unfair practices.
Requires certification of agreements between companies to ensure transparency and prevent hidden deals.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_1428
Sponsor: Sen. Klobuchar, Amy [D-MN]
Process start date: 2021-04-28
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Preserve Access to Affordable Generics and Biosimilars Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_1428.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-04-28.

What are the main provisions?

Key points include:

  • Bans payments for delaying the market entry of generic and biosimilar drugs, aiming to boost competition.
  • Introduces financial penalties for companies violating these rules, discouraging unfair practices.
  • Requires certification of agreements between companies to ensure transparency and prevent hidden deals.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Klobuchar, Amy [D-MN].

What is the latest detailed status?

The latest detailed status is: Placed on Senate Legislative Calendar under General Orders. Calendar No. 180.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

CATEGORIES

Health Courts and Law Economy